Work

A change to the pathway: The Impact of the Supreme Court of the United States affirmative action decision on clinical pharmacy and a call to action for pharmacists

Year: 2024

Type: article

Abstract: Jacinda Abdul-Mutakabbir receives support from the Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) of the National Institutes of Health (NIH) under Award Number K12HD113189. John Allen receives support from the National Cancer Institute (NCI) under Award Number U54CA233444. The content is solely the authors' responsibility and does not necessarily represent the official views of the National Institutes of Health. Jacinda Abdul-Mutakabbir has also served on advisory boards and received an honorarium for Shionogi, GSK, NovaVax, CSL Seqirus, Innoviva Specialty Therapeutics, and AbbVie. She has also received research support from CSL Seqirus. Drs. Allen and Abdul-Mutakabbir are members of the JACCP Editorial Board. All other Authors have no conflicts of interest.

Source: JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY

DOI: 10.1002/jac5.1961

Authors: Jacinda C. Abdul‐Mutakabbir, Tyler Marie Kiles, John M. Allen, Hope E. Campbell

Institutions: University of California San Diego, The University of Texas at Austin, University of Florida, Belmont University

Language: English

Topic: Pharmacy and Medical Practices

Subfield: Pharmacology

Field: Pharmacology, Toxicology and Pharmaceutics

Domain: Life Sciences

SDGs: Good health and well-being, Reduced inequalities

Open Access status: bronze

Funders: National Cancer Institute, National Institute of Allergy and Infectious Diseases, Eunice Kennedy Shriver National Institute of Child Health and Human Development